@article{APM2794,
author = {Alain Vergnenègre},
title = {How many drugs in the maintenance setting for non-small-cell lung cancer? For what benefit?},
journal = {Annals of Palliative Medicine},
volume = {2},
number = {4},
year = {2013},
keywords = {},
abstract = {Maintenance treatment has been used for several years inside clinical trials. Meta-analyses have been published. A new clinical trial (AVAPERL) has been recently published. Despite significant increase of progression-free survival (PFS), overall survival (OS) has not been changed with these strategies. Before a transfer into clinical practices and guidelines, new data on economic analyses (the cost effectiveness ratio was very high among specific studies) and quality of life are mandatory.},
issn = {2224-5839}, url = {https://apm.amegroups.org/article/view/2794}
}